top of page

Why Is the 2025–26 Flu Season Rougher Than Usual?


Background - An Evidence-Based Look at the 2025–26 Influenza Season

Influenza is a seasonal respiratory infection caused by influenza viruses. Illness severity ranges from mild to severe and can result in hospitalization or death, particularly among vulnerable populations. Influenza spreads primarily through respiratory droplets and contact with contaminated surfaces.


The 2025–26 influenza season is shaping up to be more intense and disruptive than those seen in recent years. Across North America and other regions, public health authorities and clinicians are reporting unusually early and widespread flu activity, rising hospitalizations, and increasing strain on healthcare systems. These trends have prompted renewed urgency around vaccination, early treatment, and public awareness.

 

What’s Driving the Severity?

Several factors combine this year to make influenza more severe and widespread:

 

1.  A Mutated Dominant Virus Strain

The predominant circulating virus this season is Influenza A(H3N2), particularly a newly emerged subvariant referred to as subclade K, which has demonstrated efficient global spread. Historically, H3N2-dominant seasons are associated with higher rates of hospitalization and severe disease, especially among older adults and young children.


This subclade emerged after the current flu vaccine formulation was selected, resulting in a less-than-optimal antigenic match. Despite this, the vaccine continues to provide important protection against severe illness and complications.

 

2. Early and Widespread Transmission

Unlike typical influenza seasons that peak later in winter, flu activity this year began earlier and escalated more rapidly. Many communities are experiencing high levels of illness well ahead of the usual seasonal peak, contributing to a longer and more intense overall season.

 

3. Lower Vaccination Uptake

Influenza vaccination rates remain below public health targets in many regions. Reduced uptake weakens community-level protection, allowing the virus to spread more freely and increasing the likelihood of severe disease and complications.

 

4. Post-Pandemic Immunity Gaps

Reduced exposure to influenza viruses during recent years, largely due to COVID-19 mitigation measures, has limited the development of natural immunity in many populations. When combined with a vaccine mismatch, this immunity gap leaves more individuals susceptible once influenza begins circulating widely.

 

Who Is at Highest Risk?

While anyone can contract influenza, certain populations are at substantially higher risk for severe outcomes:

 

  • Older Adults (65+)

Older adults experience the highest rates of hospitalization and influenza-related mortality. H3N2-dominant seasons disproportionately affect this age group.

 

  • Young Children

Children under 5 years, particularly those under 2, are at increased risk due to immature immune systems. Infants under 6 months are especially vulnerable because they are not eligible for vaccination.

 

  • People with Chronic Conditions

Individuals with asthma, diabetes, cardiovascular disease, obesity, immunosuppression, and other chronic illnesses face a significantly higher risk of complications and hospitalization.

 

  • Pregnant Individuals

Pregnancy alters immune function and lung capacity, increasing the risk of severe influenza. Annual influenza vaccination is strongly recommended during any trimester.

 

The Role of the Flu Vaccine

Even in seasons with imperfect strain matching, the influenza vaccine remains the most effective tool for reducing disease burden:

  • Protection Against Severe Outcomes: While this year’s vaccine does not perfectly match the dominant subclade, it significantly lowers the risk of hospitalization and severe illness, particularly in children and high-risk adults.

  • Reduced Complications: Vaccinated individuals who become infected are less likely to experience serious complications, require ICU care, or die compared with those who are unvaccinated.

  • Safety and Eligibility: Annual influenza vaccination is recommended for everyone aged 6 months and older, including pregnant individuals and those with chronic medical conditions.


This season’s recommendations also include newer vaccine formulations designed to improve immune responses in specific populations, such as older adults.

 

Treatment: What Works Once You’re Sick

Early treatment can significantly reduce the impact of influenza:

Antiviral Medications

Several antiviral medications approved in the United States, including Oseltamivir, Zanamivir, and Baloxavir. These can shorten symptom duration and reduce disease severity when started within 48 hours of symptom onset.

Early antiviral treatment is strongly recommended for:

  • Individuals at high risk of complications (including pregnant people)

  • Hospitalized patients

  • Anyone with severe, progressive, or worsening symptoms


Rapid diagnostic testing and telehealth consultations can help ensure timely initiation of treatment, which is especially critical for high-risk individuals.

 

Key Takeaways

This influenza season is more severe due to:

  • Circulation of a more aggressive, antigenically drifted virus strain

  • Lower-than-optimal vaccination coverage

  • A vaccine mismatch with the dominant subvariant, despite continued protection against severe outcomes

  • Early and widespread transmission placing strain on healthcare systems


For high-risk populations, including older adults, young children, pregnant individuals, and those with chronic conditions, prevention and prompt treatment remain essential.

 

Conclusion

Although the 2025–26 influenza season is proving more severe than recent years, proven measures such as vaccination, early medical evaluation, and appropriate antiviral treatment can save lives and reduce serious outcomes. Staying informed, protecting vulnerable populations, and working closely with healthcare providers are key to navigating this flu season safely.


References

Assessed and Endorsed by the MedReport Medical Review Board

 
 

©2025 by The MedReport Foundation, a Washington state non-profit organization operating under the UBI 605-019-306

 

​​The information provided by the MedReport Foundation is not intended or implied to be a substitute for professional medical advice, diagnosis, or treatment. The MedReport Foundation's resources are solely for informational, educational, and entertainment purposes. Always seek professional care from a licensed provider for any emergency or medical condition. 
 

Privacy Policy

Editorial Policy

Terms & Conditions

bottom of page